| Symbol | APVO |
|---|---|
| Name | APTEVO THERAPEUTICS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 2401 4TH AVENUE,SUITE 1050, SEATTLE, Washington, 98121, United States |
| Telephone | +1 206 838-0500 |
| Fax | — |
| — | |
| Website | https://www.aptevotherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001671584 |
| Description | Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells. Additional info from NASDAQ: |
Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors
Read moreNew Form SCHEDULE 13G - Aptevo Therapeutics Inc. <b>Filed:</b> 2026-06-22 <b>AccNo:</b> 0001666270-26-000004 <b>Size:</b> 7 KB
Read moreNew Form 3 - Aptevo Therapeutics Inc. <b>Filed:</b> 2026-06-22 <b>AccNo:</b> 0001666270-26-000003 <b>Size:</b> 4 KB
Read moreNew Form 3 - Aptevo Therapeutics Inc. <b>Filed:</b> 2026-05-28 <b>AccNo:</b> 0001193125-26-245818 <b>Size:</b> 11 KB
Read moreAptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer
Read moreAptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing
Read more(90% Positive) APTEVO THERAPEUTICS INC. (APVO) Announces Enrollment Update for remission Due to Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read moreAptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
Read more(80% Positive) APTEVO THERAPEUTICS INC. (APVO) Announces Enrollment Update for mipletamig Due to Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read moreAptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04973618 | Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML | Phase1 | AML | Withdrawn | 2025-01-01 | 2027-01-01 | ClinicalTrials.gov |
| NCT06634394 | APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML | Phase1 | Acute Myeloid Leukemia (AML) | Recruiting | 2024-10-01 | 2028-03-01 | ClinicalTrials.gov |
| NCT05934539 | ALG.APV-527 First-in-human Study | Phase1 | Solid Tumor | Unknown | 2022-12-23 | 2025-12-01 | ClinicalTrials.gov |
| NCT03768219 | Study to Evaluate APVO210 in Healthy Subjects, Patients With Psoriasis, and Pat… | Phase1 | Psoriasis | Terminated | 2019-03-18 | 2020-06-30 | ClinicalTrials.gov |
| NCT03647800 | Study of APVO436 in Patients With AML or MDS | Phase1 | AML | Unknown | 2018-12-13 | 2023-06-15 | ClinicalTrials.gov |
| NCT02262910 | Study of ES414 in Metastatic Castration-Resistant Prostate Cancer | Phase1 | Prostate Cancer | Completed | 2015-01-01 | 2019-02-18 | ClinicalTrials.gov |
| NCT01644253 | Phase 1b Safety and Efficacy Study of TRU-016 | Phase1 | Chronic Lymphocytic Leukemia | Terminated | 2012-09-01 | 2021-04-21 | ClinicalTrials.gov |
| NCT01317901 | A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects W… | Phase1 | B-cell Small Lymphocytic Lymphoma Recurrent | Completed | 2011-05-01 | 2013-06-01 | ClinicalTrials.gov |
| NCT01188681 | Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Rela… | Phase1 | Chronic Lymphocytic Leukemia (CLL) | Completed | 2010-09-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT00614042 | Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select S… | Phase1 | Chronic Lymphocytic Leukemia (CLL) | Completed | 2008-01-01 | 2012-03-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE1 | Psoriasis | TERMINATED | NCT03768219 |
| APVO210 | Other | Phase PHASE1 | Psoriasis | TERMINATED | NCT03768219 |
| ALG.APV-527 | Other | Phase PHASE1 | Solid Tumor | UNKNOWN | NCT05934539 |
| Rituximab | Other | Phase PHASE1 | B-cell Small Lymphocytic Lymphoma Recurrent | COMPLETED | NCT01317901 |
| Bendamustine | Other | Phase PHASE1 | B-cell Small Lymphocytic Lymphoma Recurrent | COMPLETED | NCT01317901 |
| TRU-016 | Other | Phase PHASE1 | B-cell Small Lymphocytic Lymphoma Recurrent | COMPLETED | NCT01317901 |
| ES414 | Other | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT02262910 |
| TRU-016 10-20 mg/kg + bendamustine | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01644253 |
| TRU-016 10-20 mg/kg + ibrutinib | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01644253 |
| TRU-016 6-20 mg/kg + idelalisib + rituximab | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01644253 |
| TRU-016 20 mg/kg + Obinutuzumab | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01644253 |
| 10 mg/kg TRU-016 + Rituximab | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01644253 |
| 20 mg/kg TRU-016 + Rituximab | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01644253 |
| 20 mg/kg TRU-016 and bendamustine | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia (CLL) | COMPLETED | NCT01188681 |
| 15 mg/kg TRU-016 and bendamustine | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia (CLL) | COMPLETED | NCT01188681 |
| Bendamustine | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia (CLL) | COMPLETED | NCT01188681 |
| TRU-016 and bendamustine | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia (CLL) | COMPLETED | NCT01188681 |
| APVO436 | Other | Phase PHASE1 | AML | WITHDRAWN | NCT04973618 |
| APVO436 | Other | Phase PHASE1 | AML | UNKNOWN | NCT03647800 |
| Azacitidine | Other | Phase PHASE1 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT06634394 |
| Venetoclax | Other | Phase PHASE1 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT06634394 |
| APVO436 | Other | Phase PHASE1 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT06634394 |
| Azacitidine | DRUG | Phase PHASE1 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT06634394 |
| Venetoclax | DRUG | Phase PHASE1 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT06634394 |
| ALG.APV-527 | DRUG | Phase PHASE1 | Solid Tumor | RECRUITING | NCT05934539 |
| APVO436 | DRUG | Phase PHASE1 | Acute Myeloid Leukemia (AML) | RECRUITING | NCT06634394 |
| Placebo | BIOLOGICAL | Phase PHASE1 | Psoriasis | TERMINATED | NCT03768219 |
| APVO210 | BIOLOGICAL | Phase PHASE1 | Psoriasis | TERMINATED | NCT03768219 |
| ES414 | BIOLOGICAL | Phase PHASE1 | Prostate Cancer | COMPLETED | NCT02262910 |
| TRU-016 10-20 mg/kg + bendamustine | BIOLOGICAL | Phase PHASE1 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01644253 |
| TRU-016 10-20 mg/kg + ibrutinib | BIOLOGICAL | Phase PHASE1 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01644253 |
| TRU-016 6-20 mg/kg + idelalisib + rituximab | BIOLOGICAL | Phase PHASE1 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01644253 |
| TRU-016 20 mg/kg + Obinutuzumab | BIOLOGICAL | Phase PHASE1 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01644253 |
| 10 mg/kg TRU-016 + Rituximab | BIOLOGICAL | Phase PHASE1 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01644253 |
| 20 mg/kg TRU-016 + Rituximab | BIOLOGICAL | Phase PHASE1 | Chronic Lymphocytic Leukemia | TERMINATED | NCT01644253 |
| Rituximab | DRUG | Phase PHASE1 | B-cell Small Lymphocytic Lymphoma Recurrent | COMPLETED | NCT01317901 |
| TRU-016 | DRUG | Phase PHASE1 | B-cell Small Lymphocytic Lymphoma Recurrent | COMPLETED | NCT01317901 |
| 20 mg/kg TRU-016 and bendamustine | DRUG | Phase PHASE1 | Chronic Lymphocytic Leukemia (CLL) | COMPLETED | NCT01188681 |
| 15 mg/kg TRU-016 and bendamustine | DRUG | Phase PHASE1 | Chronic Lymphocytic Leukemia (CLL) | COMPLETED | NCT01188681 |
| Bendamustine | DRUG | Phase PHASE1 | B-cell Small Lymphocytic Lymphoma Recurrent | COMPLETED | NCT01317901 |
| TRU-016 and bendamustine | DRUG | Phase PHASE1 | Chronic Lymphocytic Leukemia (CLL) | COMPLETED | NCT01188681 |
| TRU-016 (anti-CD37 protein therapeutic) | DRUG | Phase PHASE1 | Chronic Lymphocytic Leukemia (CLL) | COMPLETED | NCT00614042 |